Impact of decentralized care and the Xpert MTB/RIF test on rifampicin-resistant tuberculosis treatment initiation in Khayelitsha, South Africa

Open Forum Infectious Diseases

Volumn 2, Issue 1, 2015, Pages

  Cox, Helen S ^a   Daniels, Johnny F ^b   Muller, Odelia ^b   Nicol, Mark P ^a,c   Cox, Vivian ^b   van Cutsem, Gilles ^b   Moyo, Sizulu ^b   De Azevedo, Virginia ^d   Hughes, Jennifer ^b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b MÉDECINS SANS FRONTIÈRES   (Switzerland)

^c NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

^d City of Cape Town   (South Africa)

Author keywords

Delay; MDR TB; RR TB; Treatment; Xpert

Indexed keywords

RIFAMPICIN;

ADOLESCENT; ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; CHILD; COMMUNITY CARE; DECENTRALIZATION; DRUG RESISTANT TUBERCULOSIS; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MAJOR CLINICAL STUDY; MALE; MICROSCOPY; MORTALITY; NEWBORN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SOUTH AFRICA; SPUTUM SMEAR; TIME TO TREATMENT; TREATMENT PLANNING; TUBERCULOSIS RAPID TEST; YOUNG ADULT;

EID: 84978328517     PISSN: None     EISSN: 23288957     Source Type: Journal    
DOI: 10.1093/ofid/ofv014     Document Type: Article

References (23)

1. Zhao Y, Xu S, Wang L, et al. National survey of drug-resistant tuberculosis in China. N Engl J Med 2012; 366:2161-70.
2. Cox HS, McDermid C, Azevedo V, et al. Epidemic levels of drug resistant tuberculosis (MDR and XDR-TB) in a high HIV prevalence setting in Khayelitsha, South Africa. PLoS One 2010; 5:e13901.
3. Dharmadhikari AS, Mphahlele M, Venter K, et al. Rapid impact of effective treatment on transmission of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2014; 18:1019-25.
4. World Health Organization. Global Tuberculosis Report 2014. Geneva: World Health Organization; 2014.
5. Gandhi NR, Shah NS, Andrews JR, et al. HIV coinfection in multidrugand extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med 2010; 181:80-6.
6. Ebonwu JI, Tint KS, Ihekweazu C. Low treatment initiation rates among multidrug-resistant tuberculosis patients in Gauteng, South Africa, 2011. Int J Tuberc Lung Dis 2013; 17:1043-8.
7. Boehme CC, Nicol MP, Nabeta P, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 2011; 377:1495-505.
8. World Health Organization. Global strategy and targets for tuberculosis prevention, care and control after 2015: Report by the secretariat.World Health Organization; 2013.
9. Brust JC, Shah NS, Scott M, et al. Integrated, home-based treatment for MDR-TB and HIV in rural South Africa: an alternate model of care. Int J Tuberc Lung Dis 2012; 16:998-1004.
10. Loveday M, Wallengren K, Voce A, et al. Comparing early treatment outcomes of MDR-TB in decentralised and centralised settings in KwaZulu-Natal, South Africa. Int J Tuberc Lung Dis 2012; 16:209-15.
11. Shean KP, Willcox PA, Siwendu SN, et al. Treatment outcome and follow-up of multidrug-resistant tuberculosis patients, West Coast/Winelands, South Africa, 1992-2002. Int J Tuberc Lung Dis 2008; 12: 1182-9.
12. Heller T, Lessells RJ, Wallrauch CG, et al. Community-based treatment for multidrug-resistant tuberculosis in rural KwaZulu-Natal, South Africa. Int J Tuberc Lung Dis 2010; 14:420-6.
13. Jacobson KR, Theron D, Kendall EA, et al. Implementation of genotype MTBDRplus reduces time to multidrug-resistant tuberculosis therapy initiation in South Africa. Clin Infect Dis 2013; 56:503-8.
14. Hanrahan CF, Dorman SE, Erasmus L, et al. The impact of expanded testing for multidrug resistant tuberculosis using genotype [correction of geontype] MTBDRplus in South Africa: an observational cohort study. PLoS One 2012; 7:e49898.
15. Strategic Development Information and GIS Department CoCT. City of Cape Town-2011 Census-Khayelitsha Health District. 2013.
16. Western Cape Department of Health. Western Cape Antenatal HIV Survey 2010, 2010.
17. Medecins Sans Frontieres. Khayelitsha 2001-2011, Activity Report: 10 years of HIV/TB care at primary health care level, 2011.
18. Medecins Sans Frontieres. Scaling up diagnosis and treatment of drugresistant tuberculosis in Khayelitsha, South Africa, 2011.
19. Cox H, Hughes J, Daniels J, et al. Community-based treatment of drugresistant tuberculosis in Khayelitsha, South Africa. Int J Tuberc Lung Dis 2014; 18:441-8.
20. Barnard M, Albert H, Coetzee G, et al. Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. Am J Respir Crit Care Med 2008; 177:787-92.
21. World Health Organization. Global Tuberculosis Report 2013. Geneva: World Health Organization, 2013. Report No.: WHO/HTM/TB/2013.11.
22. Gandhi NR, Andrews JR, Brust JC, et al. Risk factors for mortality among MDR-and XDR-TB patients in a high HIV prevalence setting. Int J Tuberc Lung Dis 2012; 16:90-7.
23. Osman M, Simpson JA, Caldwell J, et al. GeneXpert MTB/RIF version G4 for identification of rifampin-resistant tuberculosis in a programmatic setting. J Clin Microbiol 2014; 52:635-7.